Volume 19, Number 12—December 2013
Dispatch
Novel Variants of Clade 2.3.4 Highly Pathogenic Avian Influenza A(H5N1) Viruses, China
Table 1
Isolate | Isolation date | Antibody titer, log2 |
|
---|---|---|---|
Re-5 | k0602 | ||
A/chicken/Jiangsu/WJ/2009(H5N1) | 2009 Dec | 4 | 8 |
A/chicken/Jiangsu/XZ/2010(H5N1) | 2010 Mar | 4 | 8 |
A/chicken/northern China/k0602/2010(H5N1) | 2010 May | 4 | 10 |
A/chicken/Shandong/k0603/2010(H5N1) | 2010 Jun | 4 | 10 |
A/chicken/eastern China/ZG56/2011(H5N1) | 2011 Dec | 4 | 5 |
A/chicken/eastern China/JX/2011(H5N1) | 2011 Dec | 3 | 7 |
A/chicken/eastern China/AH/2012(H5N1) | 2012 Sep | 4 | 1 |
Re-5 diagnostic antigen† | NA | 10 | 4 |
*Re-5 and k0602 antiserum were generated by vaccinating specific-pathogen free chickens with the commercial Re-5 vaccine (Qingdao Yebio Bioengineering Co., Ltd, Qingdao, China) and the oil-emulsified inactivated A/chicken/northern China/k0602/2010(H5N1) vaccine, respectively. HI titers against the homologous antigen/virus are shown in boldface. HI, hemagglutination inhibition; NA, not applicable.
†Qingdao Yebio Bioengineering Co., Ltd, China.
Page created: November 19, 2013
Page updated: November 19, 2013
Page reviewed: November 19, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.